問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (非在職)

Division of Cardiovascular Diseases

Division of General Internal Medicine

更新時間：2023-09-19

謝宜璋Hsieh, I-Chang
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years

  • v12001@cgmh.org.tw

  • hsiehic@ms28.hinet.net

Recruiting Trial

26Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

謝宜璋

List

60Cases

2017-11-15 - 2022-12-31

Phase III

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function

  • Condition/Disease

    Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function

  • Test Drug

    Sotagliflozin

Participate Sites
10Sites

Not yet recruiting1Sites

Terminated7Sites

江晨恩
Taipei Veterans General Hospital

Division of Cardiovascular Diseases

謝宜璋
Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

2015-10-01 - 2019-05-15

Phase III

An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures

  • Condition/Disease

    Symptomatic peripheral artery disease

  • Test Drug

    Xarelto tablet

Participate Sites
8Sites

Terminated7Sites

林宗憲
Kaohsiung Municipal Gangshan Hospital

未分科

江晨恩
Taipei Veterans General Hospital

2006-12-18 - 2010-09-07

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Terminated13Sites

2010-10-01 - 2016-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2009-01-01 - 2013-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER)

  • Condition/Disease

    Acute Coronary Symdrome

  • Test Drug

    SCH530348

Participate Sites
13Sites

Terminated13Sites

2020-02-01 - 2023-12-15

Phase III

A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

  • Condition/Disease

    Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

  • Test Drug

    ION-682884 Injection; Inotersen (ISIS 420915) Injection

Participate Sites
4Sites

Recruiting4Sites

2014-02-01 - 2016-01-30

Others

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2018-01-01 - 2019-12-31

Others

A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency in Patients With Stable Angina Pectoris.

  • Condition/Disease

    Angina

  • Test Drug

    Ranolazine

Participate Sites
3Sites

Terminated3Sites

謝宜璋
Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

2014-12-01 - 2017-07-21

Phase III

A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients with Clinically Evident Cardiovascular Disease and Receiving Statin Background Lipid Lowering Therapy: A Study for Subjects Enrolled in the FOURIER (Study 20110118) Trial

  • Condition/Disease

    Cardiovascular Disease

  • Test Drug

    AMG 145

Participate Sites
8Sites

Terminated8Sites

2009-01-20 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB